Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?
Brown
J M
JM
Department of Radiation Oncology, Stanford University School of Medicine, CA 94305.
D000818:Animals; D003131:Combined Modality Therapy; D017341:Etanidazole; D005260:Female; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use*
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D014227:Triazines; D000077704:Tirapazamine; D017341:Etanidazole